DNA Methylation Combined With Artificial Intelligence Imaging for Early Benign and Malignant Differentiation of Lung Nodules:an Observational,Single-center Clinical Trial(MAGIC Study)

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Lung cancer is the leading cause of cancer deaths,and the key to reducing mortality in lung cancer patients is early diagnosis and treatment.Currently,peripheral blood DNA methylation is a novel in vitro molecular marker for tumors.Meanwhile artificial intelligence diagnostic system can further improve the diagnostic ability.The purpose of this study is to apply the overall DNA methylation level (i.e.,methylation profile) and the altered methylation degree of specific genes as tumor diagnostic indexes,and combined with the artificial intelligence imaging technology for the early and accurate diagnosis of lung cancer,to achieve the early detection,diagnosis,and treatment of lung cancer,and to effectively reduce the mortality rate of lung cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 80
View:

• (1) Patients with pulmonary nodules diagnosed by imaging;

• (2) No contraindications to blood collection;

• (3) Voluntary completed DNA methylation testing;

• (4) Signed informed consent and performed all the study mandated procedures.

Locations
Other Locations
China
Jiangsu Province Hospital
RECRUITING
Nanjing
Contact Information
Primary
Linfu Zhou
linfu.zhou@126.com
0086-13611573618
Backup
Yichun Wang
wangyichun8702@163.com
0086-18761638702
Time Frame
Start Date: 2022-12-01
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 100
Treatments
Pulmonary Nodule Group
patient conform pulmonary nodules on CT images
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital with Nanjing Medical University

This content was sourced from clinicaltrials.gov